All manner of drugs are prescribed world wide. Every drug has a different toxicology and safety profile.

Here's Ozempic's warning and precautions:

• Pancreatitis: Has been reported in clinical trials. Discontinue promptly if
pancreatitis is suspected. Do not restart if pancreatitis is confirmed (5.2).
• Diabetic Retinopathy Complications: Has been reported in a clinical trial.
Patients with a history of diabetic retinopathy should be monitored (5.3).
• Never share an OZEMPIC pen between patients, even if the needle is changed
(5.4).
• Hypoglycemia: Concomitant use with an insulin secretagogue or insulin may
increase the risk of hypoglycemia, including severe hypoglycemia. Reducing
dose of insulin secretagogue or insulin may be necessary (5.5).
• Acute Kidney Injury: Monitor renal function in patients with renal impairment
reporting severe adverse gastrointestinal reactions (5.6).
• Hypersensitivity Reactions: Serious hypersensitivity reactions (e.g.,
anaphylaxis and angioedema) have been reported. Discontinue OZEMPIC if
suspected and promptly seek medical advice (5.7).
• Acute Gallbladder Disease: If cholelithiasis or cholecystitis are suspected,
gallbladder studies are indicated (5.8).

Cochrane: https://www.cochrane.org/about-us/news/glp-1-drugs-effective-weight-loss-more-independent-studies-needed

However, evidence on longer-term outcomes, side effects, and potential conflicts of interest remains limited or uncertain.